<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment regimens for Wilms tumor according to completed North American (COG) protocols</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment regimens for Wilms tumor according to completed North American (COG) protocols</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment regimens for Wilms tumor according to completed North American (COG) protocols</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup span="3" width="30%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="4">COG AREN0321, AREN0532, and AREN0533</td> </tr> <tr> <td class="subtitle2">Stage*</td> <td class="subtitle2">Histology and clinical factors</td> <td class="subtitle2">Chemotherapy</td> <td class="subtitle2">Radiation therapy</td> </tr> <tr> <td class="centered divider_bottom" rowspan="4">I</td> <td>Favorable histology; very low risk<sup>¶</sup></td> <td>None</td> <td>None</td> </tr> <tr> <td>Favorable histology; non-very low risk<sup>¶</sup>; without high-risk molecular markers<sup>Δ</sup></td> <td>Vincristine and dactinomycin for 19 weeks</td> <td>None</td> </tr> <tr> <td>Favorable histology; non-very low risk<sup>¶</sup>; with high-risk molecular markers<sup>Δ</sup></td> <td>Vincristine, dactinomycin, and doxorubicin for 25 weeks</td> <td>None</td> </tr> <tr class="divider_bottom"> <td>Focal or diffuse anaplasia</td> <td>Vincristine, dactinomycin, and doxorubicin for 25 weeks</td> <td>10.8 Gy flank</td> </tr> <tr> <td class="centered divider_bottom" rowspan="4">II</td> <td>Favorable histology; without high-risk molecular markers<sup>Δ</sup></td> <td>Vincristine and dactinomycin for 19 weeks</td> <td>None</td> </tr> <tr> <td>Favorable histology; with high-risk molecular markers<sup>Δ</sup></td> <td>Vincristine, dactinomycin, and doxorubicin for 25 weeks</td> <td>None</td> </tr> <tr> <td>Focal anaplasia</td> <td>Vincristine, dactinomycin, and doxorubicin for 25 weeks</td> <td>10.8 Gy flank</td> </tr> <tr class="divider_bottom"> <td>Diffuse anaplasia</td> <td>Vincristine, doxorubicin, carboplatin, cyclophosphamide, and etoposide for 30 weeks</td> <td>10.8 Gy flank</td> </tr> <tr> <td class="centered divider_bottom" rowspan="4">III</td> <td>Favorable histology; without high-risk molecular markers<sup>Δ</sup></td> <td>Vincristine, dactinomycin, and doxorubicin for 25 weeks</td> <td>10.8 Gy flank/abdomen; 10.8 Gy boost for gross disease</td> </tr> <tr> <td>Favorable histology; with high-risk molecular markers<sup>Δ</sup></td> <td>Vincristine, dactinomycin, doxorubicin, cyclophosphamide, and etoposide for 31 weeks</td> <td>10.8 Gy flank/abdomen; 10.8 Gy boost for gross disease</td> </tr> <tr> <td>Focal anaplasia</td> <td>Vincristine, dactinomycin, and doxorubicin for 25 weeks</td> <td>10.8 Gy flank/abdomen; 10.8 Gy boost for gross disease</td> </tr> <tr class="divider_bottom"> <td>Diffuse anaplasia</td> <td>Vincristine, doxorubicin, carboplatin, cyclophosphamide, and etoposide for 30 weeks</td> <td>20 Gy flank/abdomen; 10.8 Gy boost for gross disease</td> </tr> <tr> <td class="centered" rowspan="4">IV</td> <td>Favorable histology; without high-risk molecular markers<sup>Δ</sup> and lung nodule complete response at week 6</td> <td>Vincristine, dactinomycin, and doxorubicin for 25 weeks</td> <td>No lung XRT; flank XRT for local stage III<sup>◊</sup></td> </tr> <tr> <td>Favorable histology; with high-risk molecular markers<sup>Δ</sup> and/or lung nodule incomplete response at week 6</td> <td>Vincristine, dactinomycin, doxorubicin, cyclophosphamide, and etoposide for 31 weeks</td> <td>12 Gy lung; flank XRT for local stage III<sup>◊</sup></td> </tr> <tr> <td>Focal anaplasia</td> <td>Vincristine, doxorubicin, carboplatin, cyclophosphamide, and etoposide for 30 weeks</td> <td>12 Gy lung; flank XRT for local stage III<sup>◊</sup></td> </tr> <tr> <td>Diffuse anaplasia</td> <td>Vincristine, doxorubicin, carboplatin, cyclophosphamide, etoposide, and irinotecan for 36 weeks</td> <td>12 Gy lung; flank XRT for local stage III<sup>◊</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">COG: Children's Oncology Group; SIOP: International Society of Paediatric Oncology; XRT: radiation therapy.<br/>* Note that the staging systems in COG and SIOP protocols are not equivalent. COG stage is determined <strong>before</strong> surgical resection; SIOP stage is determined <strong>after</strong> preoperative chemotherapy and surgical resection.<br/>¶ According to COG protocols, very low-risk tumors are defined as meeting all of the following criteria: patient age &lt;2 years, stage I favorable histology, tumor weight &lt;550 g.<br/>Δ According to COG protocols, high-risk molecular markers refers to combined loss of heterozygosity at chromosomes 1p and 16q.<br/><span class="lozenge">◊</span> Metastatic sites other than lung were also irradiated; XRT dose varied according to metastatic site.</div><div class="graphic_reference">Additional references:

<ol>
<li>Fernandez CV, Perlman EJ, Mullen EA, et al. Clinical outcome and biological predictors of relapse after nephrectomy only for very low-risk Wilms tumor: A report From Children's Oncology Group AREN0532. Ann Surg 2017; 265:835.</li>
<li>Dix DB, Fernandez CV, Chi YY, et al. Augmentation of therapy for favorable-histology Wilms Tumor with combined loss of heterozygosity of chromosomes 1p and 16q: A report from the Children's Oncology Group studies AREN0532 and AREN0533. J Clin Oncol 2015; 33:abstr 10009.</li>
<li>Fernandez CV, Mullen EA, Chi YY, et al. Outcome and prognostic factors in stage III favorable-histology Wilms tumor: A report from the Children's Oncology Group Study AREN0532. J Clin Oncol 2018; 36:254.</li>
<li>Dix DB, Seibel NL, Chi YY, et al. Treatment of stage IV favorable histology Wilms tumor with lung metastases: A report from the Children's Oncology Group AREN0533 Study. J Clin Oncol 2018; 36:1564.</li>
</ol>

Adapted from: Dome JS, Graf N, Geller JI, et al. Advances in Wilms tumor treatment and biology: Progress through international collaboration. J Clin Oncol 2015; 33:2999.</div><div id="graphicVersion">Graphic 64794 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
